Increased TUG1 expression in breast cancer (BRC) [7], bladder cancer (BC) [15], esophageal squamous cell carcinoma (ESCC) [16], muscle-invasive bladder cancer (MIBC) [17], osteosarcoma (OSA) [18], colorectal cancer (CRC) [8], gastric cancer (GC) [19], small cell lung cancer (SCLC) [10] or clear-cell renal cell carcinoma (ccRCC) [20] patients is associated with poor survival. This evidence concerns the gene TUG1 and nonpapillary renal cell carcinoma.